Cdk5 is a key factor in tau aggregation and tangle formation in vivo
- PMID: 12765608
- DOI: 10.1016/s0896-6273(03)00259-9
Cdk5 is a key factor in tau aggregation and tangle formation in vivo
Abstract
Tau aggregation is a common feature of neurodegenerative diseases such as Alzheimer's disease, and hyperphosphorylation of tau has been implicated as a fundamental pathogenic mechanism in this process. To examine the impact of cdk5 in tau aggregation and tangle formation, we crossed transgenic mice overexpressing the cdk5 activator p25, with transgenic mice overexpressing mutant (P301L) human tau. Tau was hyperphosphorylated at several sites in the double transgenics, and there was a highly significant accumulation of aggregated tau in brainstem and cortex. This was accompanied by increased numbers of silver-stained neurofibrillary tangles (NFTs). Insoluble tau was also associated with active GSK. Thus, cdk5 can initiate a major impact on tau pathology progression that probably involves several kinases. Kinase inhibitors may thus be beneficial therapeutically.
Similar articles
-
Axonopathy, tau abnormalities, and dyskinesia, but no neurofibrillary tangles in p25-transgenic mice.J Comp Neurol. 2002 May 6;446(3):257-66. doi: 10.1002/cne.10186. J Comp Neurol. 2002. PMID: 11932941
-
Aberrant Cdk5 activation by p25 triggers pathological events leading to neurodegeneration and neurofibrillary tangles.Neuron. 2003 Oct 30;40(3):471-83. doi: 10.1016/s0896-6273(03)00627-5. Neuron. 2003. PMID: 14642273
-
Compartmentalized tau hyperphosphorylation and increased levels of kinases in transgenic mice.Neuroreport. 2001 Jul 3;12(9):2007-16. doi: 10.1097/00001756-200107030-00045. Neuroreport. 2001. PMID: 11435938
-
Role of cdk5 in the pathogenesis of Alzheimer's disease.Neurosignals. 2003 Sep-Oct;12(4-5):209-14. doi: 10.1159/000074622. Neurosignals. 2003. PMID: 14673207 Review.
-
Cdk5 as a drug target for the treatment of Alzheimer's disease.J Mol Neurosci. 2002 Dec;19(3):267-73. doi: 10.1385/JMN:19:3:267. J Mol Neurosci. 2002. PMID: 12540052 Review.
Cited by
-
Role of PIM Kinase Inhibitor in the Treatment of Alzheimer's Disease.Mol Neurobiol. 2024 May 30. doi: 10.1007/s12035-024-04257-7. Online ahead of print. Mol Neurobiol. 2024. PMID: 38816674 Review.
-
Potential Implications of miRNAs in the Pathogenesis, Diagnosis, and Therapeutics of Alzheimer's Disease.Int J Mol Sci. 2023 Nov 13;24(22):16259. doi: 10.3390/ijms242216259. Int J Mol Sci. 2023. PMID: 38003448 Free PMC article. Review.
-
Novel molecular mechanism driving neuroprotection after soluble epoxide hydrolase inhibition: Insights for Alzheimer's disease therapeutics.CNS Neurosci Ther. 2024 Apr;30(4):e14511. doi: 10.1111/cns.14511. Epub 2023 Oct 31. CNS Neurosci Ther. 2024. PMID: 37905690 Free PMC article.
-
Stem cells-derived exosomes alleviate neurodegeneration and Alzheimer's pathogenesis by ameliorating neuroinflamation, and regulating the associated molecular pathways.Sci Rep. 2023 Sep 21;13(1):15731. doi: 10.1038/s41598-023-42485-4. Sci Rep. 2023. PMID: 37735227 Free PMC article.
-
Exploring the role of COX-2 in Alzheimer's disease: Potential therapeutic implications of COX-2 inhibitors.Saudi Pharm J. 2023 Sep;31(9):101729. doi: 10.1016/j.jsps.2023.101729. Epub 2023 Aug 7. Saudi Pharm J. 2023. PMID: 37638222 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases